Skip to main content
Clinical Trials/NCT01754779
NCT01754779
Completed
Phase 2

Pharmacological Therapy for Calcium Phosphate Urolithiasis

University of Texas Southwestern Medical Center1 site in 1 country13 target enrollmentJuly 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Calcium Phosphate Kidney Stones
Sponsor
University of Texas Southwestern Medical Center
Enrollment
13
Locations
1
Primary Endpoint
Urinary Calcium Phosphate Saturation
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The investigators will examine in two studies whether citric acid or potassium citrate can reduce calcium phosphate saturation in urine of Calcium Phosphate stone formers.

Detailed Description

We will examine in two short-term placebo-controlled cross-over metabolic studies whether citric acid or potassium citrate can reduce calcium phosphate saturation in urine of CaP stone formers. The first study will be conducted in hypocitraturic CaP stone formers without hypercalciuria, and will compare the effects of potassium citrate, citric acid and placebo. The second study will be conducted in hypercalciuric CaP stone formers on a thiazide diuretic who require potassium supplementation, and will compare the effects of potassium chloride alone, potassium chloride + citric acid, and potassium citrate alone. Physicochemical assays will be applied in addition to computer-based stone risk prediction programs to assess risk of stone recurrence.

Registry
clinicaltrials.gov
Start Date
July 2012
End Date
February 16, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Naim Maalouf

Associate Professor of Medicine

University of Texas Southwestern Medical Center

Eligibility Criteria

Inclusion Criteria

  • Hypocitraturic CaP stone formers
  • urine citrate \<320mg/d
  • elevated pH as 24-hr urine pH above 6.40
  • \>21 years
  • Hypercalciuric CaP stone formers
  • 24hr urine calcium \>250mg/d in women and \>300mg/d in men prior to indapamide use
  • high pH as \>6.40 in the absence of urinary tract infection
  • \>21 years

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Urinary Calcium Phosphate Saturation

Time Frame: 2 weeks

This variable represents a ratio of the calcium phosphate saturation in a given urine sample to the calcium phosphate saturation at the point of precipitation and hence this measure has no units.

Study Sites (1)

Loading locations...

Similar Trials